SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Pastimes : The OTCBB Garbage Dump

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Wayne Rumball who wrote (2507)9/29/1999 11:07:00 AM
From: John R Resseger  Read Replies (1) of 2942
 
My Aunt ANTX just cut a deal with a big Drug company.

When it hits $3 do me a Big FF and buy 20,000shs of MRKR so tit go up 25%

Eeh

Pfizer and Antex Initiate Collaboration

GAITHERSBURG, Md., Sept. 29 /PRNewswire/ -- Antex Biologics Inc. announces a collaboration with Pfizer Inc.

"We are pleased to be working with Pfizer Inc., one of the foremost global pharmaceutical companies and one of the world's leaders in animal health products," said Theresa M. Stevens, Antex's Vice President, Corporate Development. "While specifics of the collaboration will not be disclosed, we are encouraged that Antex's proprietary platform technologies are now being applied to the development of animal vaccines."

Antex's platform technologies, ART(TM) (Antigen Receptor Technology) and NST(TM) (Nutriment Signal Transduction), have been used initially to develop human vaccines. Already, strategic collaborations have been established with the world's two leading vaccine companies, SmithKline Beecham and Pasteur Merieux Connaught. Three of Antex's human vaccines are in clinical development. Additionally, these platform technologies have provided AntexPharma, Antex's pharmaceutical wholly-owned subsidiary, with discoveries including novel antibiotic targets and new chemical entities.

Ms. Stevens continued, "Animals are prone to many bacterial infections. There is a great need for the development of new vaccines and antibiotics to treat and prevent them. We see this collaboration as an important step toward our long-range business strategy (1) to leverage Antex's expertise in infectious diseases and (2) to apply our proprietary technologies toward developing products for not only human, but also animal health. Given our successes to date in developing novel human vaccines, we are encouraged that our expertise will be successfully applied to animal vaccines as well."

Antex Biologics is a biopharmaceutical company committed to improving health by developing new products to prevent and treat infections and related diseases. The Company's common stock is quoted on the OTC Bulletin Board under the ticker symbol ANTX.

Statements contained herein that are not historical facts may be forward- looking statements that are subject to a variety of risks and uncertainties. There are a number of important factors that could cause actual results to differ materially from those expressed in any forward-looking statements made by the Company. Such factors are fully described in the Company's Form 10-KSB filed with the United States Securities and Exchange Commission, and include, but are not limited to: (i) the Company's ability to fund its future operations; (ii) the Company's ability to successfully complete product research and development, including preclinical and clinical studies and commercialization; (iii) the Company's ability to obtain required governmental approvals; (iv) the Company's ability to attract and/or maintain manufacturing, sales, distribution and marketing partners; and (v) the Company's ability to develop and commercialize its products before its competitors.

SOURCE Antex Biologics Inc.

CO: Antex Biologics Inc.; Pfizer Inc.

ST: Maryland


Views: Basic - Detailed - Realtime Check Portfolio NEW!
ANTEX BIOLOGICS INC (OTC BB:ANTX) - messages - chart - links - Co. Sleuth - profile
Last Trade
11:08 AM - 0.4680 Change
+0.0930 - (+24.80%) Volume
87,800
Day's Range
0.4060 - 0.5310 Bid
0.5310 Ask
0.5620 Open
0.4060 Prev Cls
0.3750
52-week Range
N/A Bid Size
2,500 Ask Size
2,500 Last Size
1,000 Bid Tick
N/A
Quotes as of 11:08:18 AM.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext